Journal
CANCER LETTERS
Volume 264, Issue 2, Pages 241-249Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2008.01.035
Keywords
pancreatic cancer; imatinib; MEK inhibitor; MEK-MAPK; growth inhibition
Categories
Ask authors/readers for more resources
Imatinib mesylate (imatinib) inhibits the c-Kit-dependent tyrosine kinase activities and highly effective ill the treatment of CML and GIST patients. Although pancreatic cancer is reported to express c-Kit, imatinib does not effectively inhibit pancreatic cancer cell growth at physiological concentrations. Therefore, we investigated the mechanism of resistance of pancreatic cancer to imatinib treatment. Imatinib inhibited growth of pancreatic cancer cell lines in concentration and time-dependent fashion regardless of c-Kit expression. However, 5 mu M imatinib, which is almost a mean maximal plasma concentration in clinical setting, failed to suppress pancreatic cancer cell growth. Western blot analysis demonstrated that 5 mu M imatinib treatment for 1 h activated the MEK-MAPK pathway and the activation was independent of Ras activation. Administration of 5 mu M imatinib and 1 mu M U0126 (MEK inhibitor) significantly suppressed pancreatic cell growth. Our results indicate that a combination therapy of imatinib and MEK inhibitor call be a new therapeutic strategy to suppress the progression of pancreatic cancer. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available